# A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET

> **NCT05482971** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **PharmaEssentia** · enrollment: 91 (actual)

## Conditions studied

- Essential Thrombocythemia

## Interventions

- **DRUG:** Ropeginterferon alfa-2b-njft (P1101)

## Key facts

- **NCT ID:** NCT05482971
- **Lead sponsor:** PharmaEssentia
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-09-29
- **Primary completion:** 2025-05-09
- **Final completion:** 2027-03-31
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2025-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05482971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05482971, "A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05482971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*